INTRODUCTION
Breast cancer is the most common cancer among women in South Korea. A total of 11,275 women were newly diagnosed as having breast cancer in 2006 and the agestandardized incidence rate per 100,000 was 35.5. Purpose: This study aims to evaluate the cost-effectiveness of two aromatase inhibitors for the adjuvant treatment of women with postmenopausal hormone receptor positive early breast cancer, and to find the most reasonable treatment option when the population is stratified by the nodal status. Methods: A Markov model was developed with defining six Markov states based on breast cancer progression. The annual probabilities of recurrence by adjuvant treatment (anastrozole, letrozole, and tamoxifen) were estimated from the published studies in the overall population and in the node negative and node positive groups. The costs of the defined breast cancer events were measured by the micro-costing method based on the 2009 National Health Insurance Fee Schedule and the third Clinical Guideline of Breast Cancer Treatment. Anastrozole and letrozole were compared with tamoxifen respectively, using the same Markov model. The incremental cost-effectiveness ratios for the overall population and each subgroup were estimated. Results: Anastrozole was more effective and costly than tamoxifen with anastrozole costing an additional Korean Won (KRW) 22,461,689 per quality-adjusted life year (QALY). Letrozole showed a similar incremental cost of KRW 21,004,142 per QALY. In the node negative group, anastrozole was the most cost-effective with an incremental cost of KRW 19, 717 ,770 per QALY, while letrozole was the most cost-effective with an incremental cost of KRW 8, 150 ,512 per QALY for the node positive group. The sensitivity analysis showed that these results were robust.
Conclusion:
The subgroup analysis clearly demonstrated which treatment was superior among the aromatase inhibitors in terms of the cost-effectiveness. Such a finding was not confirmed for the case of the overall population. The implication of this study is that the decision makers should be careful when generalizing the cost-effectiveness results. The stratified analysis in this context may help reach a reasonable decision for allocating medical resources. However, the higher cost of aromatase inhibitors, against a background of increasing fiscal constraints on healthcare budgets, could limit the availability of this new treatment.
Economic evaluation is an analysis that compares a technology' s cost and effectiveness in a real world setting and the result is shown as a cost-effectiveness ratio. (10) To be cost-effective, a new technology should generate more health gains for the patients than it displaces as a result of any additional cost imposed on the system (opportunity cost). This trade-off is assessed by comparing the incremental cost per final health outcome, which is usually presented as the quality-adjusted life years (QALY) gained. 
Model estimation Probabilities of breast cancer events
The annual probabilities regarding breast cancer recurrence were estimated using published data, including the EBCTCG meta-analysis, the ATAC trial and the BIG 1-98 trial. For the patients receiving tamoxifen, the annual probabilities of the first breast cancer events in the years 1-5 of this model were obtained from the ATAC and BIG 1-98 trials. For extrapolation after year 6, this annual probability of recurrence was adjusted using the annual trend of recurrence presented from the EBCTCG metaanalysis, which reported the annual probability of recurrence with tamoxifen treatment for 15 yr. For anastrozole and letrozole, the probabilities of first breast cancer events were obtained by multiplying the probabilities for tamoxifen by the HR for breast cancer recurrence from the ATAC trial(5,6,13) and the BIG 1-98 trial, (7, 8) respectively ( Table 1 ). The proportions of the first breast cancer events, which would be contralateral tumor, locoregional recurrence and distant recurrence, were based on the distribution of first events among the Korean breast cancer women by applying Yang' s study (5%, 17%, and 78%, respectively). (14) The annual probabilities of recurrence following contralateral tumor were estimated from the 1998 EBCTCG meta-analysis. ( 3) The annual probabilities of distant metastases among the patients with locoregional recurrence were estimated by pooling the eight studies that reported such data. (15) (16) (17) (18) (19) (20) (21) (22) It was assumed that the relative frequencies of locoregional recurrence and distant metastases following contralateral tumor would be the same as those of the disease-free patients according to the previous cost-effectiveness analysis studies ( Table   2 ). (23, 24) When subgroup analysis was performed, different HR values by the nodal status were used. For the node negative group, the HR of anastrozole vs. tamoxifen for first breast cancer events was 0.69 (95% CI, 0.43-0.95), (12) (Table 4) .
Probabilities of death
The age-specific annual probabilities of death for women without distant metastases or adverse events were obtained from the age-specific mortality rates for the Korean female population,(31) with excluding the mortality rates due to breast cancer and the adverse events defined in this study (Table 5 ).
The annual probability of death among the women with 
Costs of adjuvant hormonal therapy
The costs of adjuvant treatment with tamoxifen, anas- (Table 6 ).
Costs of breast cancer events
The costs that occur in each breast cancer state, including Table 7 .
Costs of the adverse events and the non-health care costs
The average cost of each adverse event related to adju- 
Utility values
No previous study in Korea has reported the utility values by the disease status of women with breast cancer. We estimated the utility values by pooling the data from the studies of the UK and US, which investigated preferences for the disease states associated with breast cancer. (41, 42) 
Sensitivity analyses
When conducting the deterministic sensitivity analysis, the key model parameters, including probabilities, cost and relative risks, were varied from 50% to 150% of the base-case values. The results for the model timeframe of 25 yr and a drug price reduction by 10% were also generated. The role of a discount rate was also examined in the sensitivity analysis, with the range of 3% to 7%.
RESULTS

Base-case analysis
Anastrozole and letrozole both showed additional health benefits versus tamoxifen and they were more costly than tamoxifen as well. In the first model, which analyzed anastrozole versus tamoxifen, the discounted QALY were shown as 11.36 and 11.13, respectively, while the discounted KRW=Korean Won; QALY=quality-adjusted life year; ICER=incremental cost-effectiveness ratio. In the second model where letrozole and tamoxifen were analyzed, the discounted QALY were shown as 11.37 and 11.08, respectively, while the discounted lifetime cost of letrozole and tamoxifen were KRW 15,404,289 and KRW 9,419,457, respectively. These increases in the expected cost and health outcome were combined and this produced an incremental cost-effectiveness ratio (ICER). When the ICERs of anastrozole and letrozole were compared in the overall population, it was not confirmative to decide which treatment was superior because their cost per QALY was similar to each other. However, when subgroup analysis was conducted, it became clear that anastrozole was more cost-effective than letrozole for the node negative group and letrozole was more cost-effective than anastrozole for the node positive group (Table 8) .
Sensitivity analyses
Because the costs of adjuvant treatment were a major part of the total treatment costs for early breast cancer, cost-effectiveness was sensitive to the reduction of price of aromatase inhibitors. Also, cost-effectiveness was relatively sensitive to the probability of death due to dis- The lack of observed survival benefits as well as longterm effects on the benefits and toxicities creates challenges to accurately forecast the cost-effectiveness ratios.
This is a common challenge with modeling and it is generally resolved with appropriate assumptions and extrapolations. The assumptions can be supported by reliable, accepted literature or similar sources. In this study, it was assumed that the relative frequencies of locoregional recurrence and distant metastases following contralateral tumor would be the same as that in the diseasefree patients according to the previous cost-effectiveness analysis studies. (23, 24) There has been no literature that has reported the long-term recurrence rate after the occurrence of contralateral breast cancer.
Indirect cost was considered in this study using the productivity approach to estimate the cost of pre-mature death due to breast cancer. The loss of productivity during hospitalization or a doctor visit was also considered. However, the population of this study was post-menopausal women aged 50 and they usually do not participate in economic activities. Because the estimated loss of productivity in terms of lost income among Korean women aged 50 or older was very small, we did not include these costs regarding productivity.
To obtain the utility value of the breast cancer states among Korean women, this study inevitably used pub- The progress in the methodology of economic evaluation, therefore, has been focused on how to reduce the bias from using different sources of data and how to appropriately extrapolate lifetime effectiveness and costs. To use relative risk or hazard ratio with baseline characteristics being controlled for is one of the good practices for the economic modeling using secondary data. In this study, we used secondary data source to estimate the effectiveness of each treatment, but we estimated the treatment cost in Korean context using the micro-costing method. We suggest that the results of this study could be applied to Korean patients.
CONCLUSION
The findings of this study were summarized as follows.
First, anastrozole and letrozole were both cost-effective treatments compared to tamoxifen. Second, when anastrozole and letrozole were compared indirectly in the overall population, their cost-effectiveness ratios were too similar to decide which treatment was superior to the other. Third, when the population was divided by the nodal status, it became clear that anastrozole was more cost-effective than letrozole in the node negative group and letrozole was more cost-effective than anastrozole in the node positive group. The decision makers of health policy need to be careful when generalizing these costeffectiveness results to the overall population. The subgroup results in this context can be used to more efficiently allocate resources and to enhance the value of the decisions that are made on health policy in Korea.
